| |||
Names | |||
---|---|---|---|
IUPAC name
(5R)-5-(Piperidine-1-carbonyl)pyrrolidin-2-one
| |||
Other names | |||
Identifiers | |||
3D model (
JSmol)
|
|||
ChEMBL | |||
ChemSpider | |||
KEGG | |||
PubChem
CID
|
|||
UNII | |||
CompTox Dashboard (
EPA)
|
|||
| |||
| |||
Properties | |||
C10H16N2O2 | |||
Molar mass | 196.250 g·mol−1 | ||
Pharmacology | |||
Oral | |||
Legal status |
| ||
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
Fasoracetam is a research chemical of the racetam family. [3] It is a putative nootropic that failed to show sufficient efficacy in clinical trials for vascular dementia. It is currently being studied for its potential use for attention deficit hyperactivity disorder. [2] [4]
Fasoracetam appears to agonize all three groups of metabotropic glutamate receptors and has improved cognitive function in rodent studies. [5] It is orally bioavailable and is excreted mostly unchanged via the urine. [6]
Fasoracetam was discovered by scientists at the Japanese pharmaceutical company Nippon Shinyaku, which brought it through Phase 3 clinical trials for vascular dementia, and abandoned it due to lack of efficacy. [5] [7]
Scientists at Children's Hospital of Philadelphia led by Hakon Hakonarson have studied fasoracetam's potential use in attention deficit hyperactivity disorder. [5] Hakonarson's company neuroFix tried to bring the drug to market for this use; neuroFix acquired Nippon Shinyaku's clinical data as part of its efforts. [7] [8] neuroFix was acquired by Medgenics in 2015. [8] Medgenics changed its name to Aevi Genomic Medicine in 2016. [9]
Clinical trials in adolescents with ADHD who also have mGluR mutations started in 2016. [8] While Fasoracetam may be effective in the treatment of ADHD in people with specific mGluR mutations, these represent around 10% of total ADHD cases, and Fasoracetam is likely ineffective in all other cases. [10] [11] Studies showing improvements in cognitive function from fasoracetam have exclusively been done on rodents. [10]
Fasoracetam is a schedule 4 substance in Australia under the Poisons Standard (February 2020). [12] A schedule 4 substance is classified as "Prescription Only Medicine, or Prescription Animal Remedy – Substances, the use or supply of which should be by or on the order of persons permitted by State or Territory legislation to prescribe and should be available from a pharmacist on prescription." [12]
| |||
Names | |||
---|---|---|---|
IUPAC name
(5R)-5-(Piperidine-1-carbonyl)pyrrolidin-2-one
| |||
Other names | |||
Identifiers | |||
3D model (
JSmol)
|
|||
ChEMBL | |||
ChemSpider | |||
KEGG | |||
PubChem
CID
|
|||
UNII | |||
CompTox Dashboard (
EPA)
|
|||
| |||
| |||
Properties | |||
C10H16N2O2 | |||
Molar mass | 196.250 g·mol−1 | ||
Pharmacology | |||
Oral | |||
Legal status |
| ||
Except where otherwise noted, data are given for materials in their
standard state (at 25 °C [77 °F], 100 kPa).
|
Fasoracetam is a research chemical of the racetam family. [3] It is a putative nootropic that failed to show sufficient efficacy in clinical trials for vascular dementia. It is currently being studied for its potential use for attention deficit hyperactivity disorder. [2] [4]
Fasoracetam appears to agonize all three groups of metabotropic glutamate receptors and has improved cognitive function in rodent studies. [5] It is orally bioavailable and is excreted mostly unchanged via the urine. [6]
Fasoracetam was discovered by scientists at the Japanese pharmaceutical company Nippon Shinyaku, which brought it through Phase 3 clinical trials for vascular dementia, and abandoned it due to lack of efficacy. [5] [7]
Scientists at Children's Hospital of Philadelphia led by Hakon Hakonarson have studied fasoracetam's potential use in attention deficit hyperactivity disorder. [5] Hakonarson's company neuroFix tried to bring the drug to market for this use; neuroFix acquired Nippon Shinyaku's clinical data as part of its efforts. [7] [8] neuroFix was acquired by Medgenics in 2015. [8] Medgenics changed its name to Aevi Genomic Medicine in 2016. [9]
Clinical trials in adolescents with ADHD who also have mGluR mutations started in 2016. [8] While Fasoracetam may be effective in the treatment of ADHD in people with specific mGluR mutations, these represent around 10% of total ADHD cases, and Fasoracetam is likely ineffective in all other cases. [10] [11] Studies showing improvements in cognitive function from fasoracetam have exclusively been done on rodents. [10]
Fasoracetam is a schedule 4 substance in Australia under the Poisons Standard (February 2020). [12] A schedule 4 substance is classified as "Prescription Only Medicine, or Prescription Animal Remedy – Substances, the use or supply of which should be by or on the order of persons permitted by State or Territory legislation to prescribe and should be available from a pharmacist on prescription." [12]